Log In Sign up
The largest database of trusted experimental protocols

Promus premier

Manufactured by Boston Scientific
Visit Supplier
Sourced in United States

The Promus Premier is a drug-eluting stent system designed for the treatment of coronary artery disease. It features a cobalt chromium alloy platform and a durable, biocompatible polymer coating that delivers a controlled release of the antiproliferative drug everolimus to prevent restenosis.

Automatically generated - may contain errors

Lab products found in correlation

Resolute integrity, by Medtronic (10 mentions) Synergy 2, by Boston Scientific (6 mentions) Xience prime, by Abbott (5 mentions) Promus element, by Boston Scientific (4 mentions) Xience xpedition, by Abbott (2 mentions) Ultimaster, by Terumo (2 mentions) Resolute onyx, by Medtronic (2 mentions) Xience 5, by Abbott (2 mentions) Multilink 8, by Abbott (1 mentions) Xience pro, by Abbott (1 mentions) Nobori, by Terumo (1 mentions) Promus, by Boston Scientific (1 mentions) Promus element plus, by Boston Scientific (1 mentions)

Close spelling variants of this product

Promus

11 protocols using promus premier

1

Balloon Catheter Hypotube Strength Comparison

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 5

The strength of the hypotube of the balloon catheter in accordance with the disclosed subject matter prepared as described above was tested and compared to known balloon catheters including the Synergy II® (commercially available from Boston Scientific), Promus Premier® (commercially available from Boston Scientific), and Resolute Integrity® (commercially available from Medtronic). The strength of the hypotube was tested by applying a bending force perpendicular to the main axis of a straight portion of the hypotube until it is bent by 90°. The higher the force it takes to bend the hypotube a certain angle (bending modulus), the higher its bending resistance and thus its strength. The results of the testing are shown in FIG. 19, which plots the bending resistance (in-lb) against the angle. A higher bending resistance represents a stronger hypotube. As depicted in FIG. 19, catheters in accordance with the disclosed subject matter having a hypotube with the dimensions and the stepped skive provided herein unexpectedly provide improved strength as compared to commercially available catheters. For example, the catheter in accordance with the disclosed subject matter was up 60% stronger than commercially available catheters, which can provide improved push transmission, a reduction in the tendency to kink, and smoother force transfer and tactile feedback.

US10086175B2. Balloon catheter (2018-10-02). Abbott Cardiovascular Systems Inc. [US]. Inventors: Hector Torres [US], Bruce Wilson [US], Thomas Haslinger [US].
+ Open protocol
+ Expand
2

Improved Distal Tensile Strength of Balloon Catheters

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 4

The strength of distal outer member in accordance with the disclosed subject matter prepared as described above was tested and compared to known balloon catheters including the Synergy II® (commercially available from Boston Scientific), Promus Premier® (commercially available from Boston Scientific), and Resolute Integrity® (commercially available from Medtronic). Distal outer member strength was tested by applying a tensile force to determine the strength of the distal section of a device. Higher force values indicate a higher distal tensile strength. The results of the testing are shown in FIG. 18, which shows that catheters in accordance with the disclosed subject matter having a single layer necked PEBAX® 72D outer member unexpectedly provide improved strength as compared to commercially available catheters. For example, the catheter in accordance with the disclosed subject matter was up 21% stronger than commercially available catheters, which can provide improved strength in navigating complex anatomy and reduce the likelihood of rupture/failure.

US10709876B2. Balloon catheter (2020-07-14). ABBOTT CARDIOVASCULAR SYSTEMS INC. [US]. Inventors: Hector Torres [US], Bruce Wilson [US], Thomas Haslinger [US].
+ Open protocol
+ Expand
3

Improved Balloon Catheter Pushability

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 3

The pushability of the balloon catheter in accordance with the disclosed subject matter prepared as described above was tested and compared to known balloon catheters including the Synergy II® (commercially available from Boston Scientific), Promus Premier® (commercially available from Boston Scientific), and Resolute Integrity® (commercially available from Medtronic). Pushability (i.e., push efficiency) was tested by applying a known force to the proximal end of a catheter placed in a tortuosity fixture over a guide wire (simulating a tortuous anatomy) and measuring how much of this force is transmitted to the distal end of the catheter. Higher ratios of distal force over proximal force indicate higher pushability. The results of the testing are shown in FIG. 17, which shows the pushability of the catheter. As depicted, catheters in accordance with the disclosed subject matter having a hypotube with a stepped skive in combination with a zero transmission (i.e., monolithic) inner member unexpectedly provide improved pushability as compared to commercially available catheters. For example, the catheter in accordance with the disclosed subject matter provided up to 33% improved pushability than commercially available catheters, which can improve delivery of the catheter to, including time needed to reach, the target site in a patient.

US10709876B2. Balloon catheter (2020-07-14). ABBOTT CARDIOVASCULAR SYSTEMS INC. [US]. Inventors: Hector Torres [US], Bruce Wilson [US], Thomas Haslinger [US].
+ Open protocol
+ Expand
4

Balloon Catheter Hypotube Strength Comparison

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 5

The strength of the hypotube of the balloon catheter in accordance with the disclosed subject matter prepared as described above was tested and compared to known balloon catheters including the Synergy II® (commercially available from Boston Scientific), Promus Premier® (commercially available from Boston Scientific), and Resolute Integrity® (commercially available from Medtronic). The strength of the hypotube was tested by applying a bending force perpendicular to the main axis of a straight portion of the hypotube until it is bent by 90°. The higher the force it takes to bend the hypotube a certain angle (bending modulus), the higher its bending resistance and thus its strength. The results of the testing are shown in FIG. 19, which plots the bending resistance (in-lb) against the angle. A higher bending resistance represents a stronger hypotube. As depicted in FIG. 19, catheters in accordance with the disclosed subject matter having a hypotube with the dimensions and the stepped skive provided herein unexpectedly provide improved strength as compared to commercially available catheters. For example, the catheter in accordance with the disclosed subject matter was up 60% stronger than commercially available catheters, which can provide improved push transmission, a reduction in the tendency to kink, and smoother force transfer and tactile feedback.

US10709876B2. Balloon catheter (2020-07-14). ABBOTT CARDIOVASCULAR SYSTEMS INC. [US]. Inventors: Hector Torres [US], Bruce Wilson [US], Thomas Haslinger [US].
+ Open protocol
+ Expand
5

Distal Outer Member Tensile Strength

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 4

The strength of distal outer member in accordance with the disclosed subject matter prepared as described above was tested and compared to known balloon catheters including the Synergy II® (commercially available from Boston Scientific), Promus Premier® (commercially available from Boston Scientific), and Resolute Integrity® (commercially available from Medtronic). Distal outer member strength was tested by applying a tensile force to determine the strength of the distal section of a device. Higher force values indicate a higher distal tensile strength. The results of the testing are shown in FIG. 18, which shows that catheters in accordance with the disclosed subject matter having a single layer necked PEBAX® 72 D outer member unexpectedly provide improved strength as compared to commercially available catheters. For example, the catheter in accordance with the disclosed subject matter was up 21% stronger than commercially available catheters, which can provide improved strength in navigating complex anatomy and reduce the likelihood of rupture/failure.

US10086175B2. Balloon catheter (2018-10-02). Abbott Cardiovascular Systems Inc. [US]. Inventors: Hector Torres [US], Bruce Wilson [US], Thomas Haslinger [US].
+ Open protocol
+ Expand
6

Comparison of Five Stent Platforms

Check if the same lab product or an alternative is used in the 5 most similar protocols
We compared five platforms: Omega (Boston Scientific), Multilink 8 (Abbott Vascular, Redwood City, California, USA), Integrity (Medtronic, Minneapolis, USA), Biomatrix Flex (Biosensors, Singapore) and Promus Premier (Boston Scientific). The former three bare metal stents were chosen as they are the identical platforms to the drug-eluting Promus and Taxus Element (Boston Scientific), Xience Prime (Abbott Vascular,) and Resolute Integrity (Medtronic) stents, respectively. The Biomatrix Flex and Promus Premier stents do not have bare metal equivalents. We chose 3.5 mm diameter stents for all platforms to avoid testing a mixture of small and large vessel platforms that exist for 3 mm diameter stents depending on the manufacturer. Stent length was greater than 18 mm in all cases. Table 1 shows the stent platform structures and characteristics for the stents used.
Choudhury T.R., Al-Saigh S., Burley S., Li L., Shakhshir N., Mirhosseini N., Wang T., Arnous S., Khan M.A., Mamas M.A, & Fraser D.G. (2017). Longitudinal deformation bench testing using a coronary artery model: a new standard?. Open Heart, 4(2), e000537.
+ Open protocol
+ Expand
7

Improved Balloon Catheter Pushability

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 3

The pushability of the balloon catheter in accordance with the disclosed subject matter prepared as described above was tested and compared to known balloon catheters including the Synergy II® (commercially available from Boston Scientific), Promus Premier® (commercially available from Boston Scientific), and Resolute Integrity® (commercially available from Medtronic). Pushability (i.e., push efficiency) was tested by applying a known force to the proximal end of a catheter placed in a tortuosity fixture over a guide wire (simulating a tortuous anatomy) and measuring how much of this force is transmitted to the distal end of the catheter. Higher ratios of distal force over proximal force indicate higher pushability. The results of the testing are shown in FIG. 17, which shows the pushability of the catheter. As depicted, catheters in accordance with the disclosed subject matter having a hypotube with a stepped skive in combination with a zero transmission (i.e., monolithic) inner member unexpectedly provide improved pushability as compared to commercially available catheters. For example, the catheter in accordance with the disclosed subject matter provided up to 33% improved pushability than commercially available catheters, which can improve delivery of the catheter to, including time needed to reach, the target site in a patient.

US10086175B2. Balloon catheter (2018-10-02). Abbott Cardiovascular Systems Inc. [US]. Inventors: Hector Torres [US], Bruce Wilson [US], Thomas Haslinger [US].
+ Open protocol
+ Expand
8

Bioresorbable Scaffolds vs. Drug-Eluting Stents in CTO PCI

Check if the same lab product or an alternative is used in the 5 most similar protocols
The only BRS used in this study was Absorb. However, several second-generation DES were used: Xience Prime, Xience Xpedition, and Xience Pro X (Abbott Vascular); Promus Premier, Promus Element and Synergy (Boston Scientific, Marlborough, MA); Resolute Integrity and Resolute Onyx (Medtronic, Minneapolis, MN); Nobori and Ultimaster (Terumo, Tokyo, Japan); BioMatrix (Biosensors International, Singapore); Combo (OrbusNeich, Hong Kong); Xposition S (Stentys, Paris, France); and Cre8 (Alvimedica, Istanbul, Turkey).
BRS implantation was performed as recommended by expert consensus (aggressive lesion preparation, appropriate sizing, routine intravascular imaging guidance, and high-pressure postdilatation with noncompliant balloons with a balloon-to-artery ratio of ≈1). 10 (link) DES implantation technique was left at the operator discretion. Figures 1 and2 show examples of CTO PCI with BRS and DES, respectively.
Azzalini L., Giustino G., Ojeda S., Serra A., La Manna A., Ly H.Q., Bellini B., Benincasa S., Chavarría J., Gheorghe L.L., Longo G., Miccichè E., D'Agosta G., Picard F., Pan M., Tamburino C., Latib A., Carlino M., Chieffo A, & Colombo A. (2016). Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions: The BONITO Registry (Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions). Circulation. Cardiovascular interventions, 9(10).
+ Open protocol
+ Expand
9

Evaluation of Stent Implantation in Patients with Stent Failure

Check if the same lab product or an alternative is used in the 5 most similar protocols
All interventions were performed using standard techniques. Predilation, postdilation, and use of intracoronary imaging (intravascular ultrasound (IVUS) or optical coherence tomography (OCT)) were left to the operator's discretion, as well as the decision to implant a further stent in patients with ESV-confirmed SF. ESV system utilization was mandatory after stent implantation and after postdilation (if it was performed). The following DES were implanted: Xience V or Xience Prime or Xience PRO (Abbott Vascular, Santa Clara, CA, USA), Promus Element or Promus Premier (Boston Scientific, Natick, MA, USA), Biomatrix Flex (Biosensors Europe SA, Morges, Switzerland), and Cre8 (CID and Alvimedica. S.P.A., Saluggia, Italy). After the procedure, all patients were advised to continue dual antiplatelet therapy (DAPT) with aspirin and P2Y12 inhibitor months after 2nd-generation DES implantation in patients with SF-predisposing factors. Secondary endpoints were: (1) any component of the primary endpoint; (2) definite and probable stent thrombosis (ST), and (3) target vessel revascularization (TVR). Finally, as a preliminary analysis, we compared the occurrence of the primary endpoint in patients with SF III-IV stratified according to the implantation (or not) of a further stent. All endpoints were adjudicated by an independent reviewer (R.P.), who was unaware of any data.
Biscaglia S., Tebaldi M., Tumscitz C., Pavasini R., Marchesini J., Gallo F., Spitaleri G., Zaraket F., Serenelli M., Cimaglia P., Bugani G, & Campo G. (2016). Prospective Identification of Stent Fracture by Enhanced Stent Visualization System During Percutaneous Coronary Intervention. Circulation journal : official journal of the Japanese Circulation Society, 81(1).
+ Open protocol
+ Expand
10

Invasive Treatment Strategies for Acute Coronary Syndromes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Patients with ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI), or unstable angina pectoris were treated using early invasive treatment strategies.
Stent implantation was performed according to current standard techniques. The 2nd DES used included Xience V, Xience Prime, Xience Expedition (Abbott Vascular, Santa Clara, CA, USA), Promus, Promus Element, Promus Premier (Boston Scientific, Natick, MA, USA), Nobori (TERUMO, Tokyo, Japan), and Resolute Integrity (Medtronic, Minneapolis, MN, USA). Several details, including the approach site (radial versus femoral), type of guiding catheter, guide wire, and other technical issues, were left to the operator's discretion.
Honda Y., Yamawaki M., Mori S., Shirai S., Makino K., Tokuda T., Maruyama T., Takafuji H., Takama T., Tsutumi M., Sakamoto Y., Takimura H., Kobayashi N., Araki M., Hirano K., Sakai T, & Ito Y. (2017). Frequency and predictors of bleeding events after 2nd generation drug-eluting stent implantation differ depending on time after implantation. Journal of cardiology, 69(4).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!